Phase Ib/IIa, to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects With Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Safety, Pharmacokinetics
Tim Meyer, PhD, MD
Principal Investigator
Royal Free Hospital
United Kingdom: Medicines and Healthcare Products Regulatory Agency
01010106E
NCT00288925
September 2005
Name | Location |
---|